GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Days Sales Outstanding

Fennec Pharmaceuticals (TSX:FRX) Days Sales Outstanding : 147.20 (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Days Sales Outstanding?

Fennec Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2025 was C$20.27 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Mar. 2025 was C$12.56 Mil. Hence, Fennec Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2025 was 147.20.

The historical rank and industry rank for Fennec Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

TSX:FRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.33   Med: 89.12   Max: 367.45
Current: 149.87

During the past 13 years, Fennec Pharmaceuticals's highest Days Sales Outstanding was 367.45. The lowest was 81.33. And the median was 89.12.

TSX:FRX's Days Sales Outstanding is ranked worse than
82.55% of 848 companies
in the Biotechnology industry
Industry Median: 70.36 vs TSX:FRX: 149.87

Fennec Pharmaceuticals's Days Sales Outstanding increased from Mar. 2024 (34.18) to Mar. 2025 (147.20).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.


Fennec Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Fennec Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Days Sales Outstanding Chart

Fennec Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 367.45 89.12 81.33

Fennec Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.18 141.10 165.94 144.83 147.20

Competitive Comparison of Fennec Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Fennec Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Days Sales Outstanding falls into.


;
;

Fennec Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Fennec Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (11.825 + 18.356) / 2 ) / 67.727*365
=15.0905 / 67.727*365
=81.33

Fennec Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding (Q: Mar. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Mar. 2025 )) / count ) / Revenue (A: Mar. 2025 )*Days in Period
=( (18.356 + 22.177) / 2 ) / 12.563*365 / 4
=20.2665 / 12.563*365 / 4
=147.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fennec Pharmaceuticals  (TSX:FRX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Fennec Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Chris Anigeron Rallis Director
Rostislav Christov Raykov Director, Senior Officer
Robert Christopher Andrade Senior Officer
Adrian J. Haigh Senior Officer
Khalid Islam Director

Fennec Pharmaceuticals Headlines

From GuruFocus

Forest Road Letter to Stockholders

By Business Wire Business Wire 06-01-2021

Beachbody CEO Letter to Forest Road Shareholders

By Business Wire Business Wire 06-09-2021